kabutan

Kidswell Bio Corporation(4584) Summary

4584
TSE Growth
Kidswell Bio Corporation
266
JPY
-5
(-1.85%)
Mar 13, 3:30 pm JST
1.66
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
265
Mar 13, 11:19 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.02
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
263 JPY 1.65 USD
Previous Close Mar 12
271 JPY 1.70 USD
High Mar 13, 10:04 am
271 JPY 1.70 USD
Low Mar 13, 9:06 am
256 JPY 1.60 USD
Volume
1,187,200
Trading Value
0.31B JPY 1.95M USD
VWAP
262.47 JPY 1.65 USD
Minimum Trading Value
26,600 JPY 166 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
853
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
1,216
1-Year High Jan 22, 2026
11,856
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 4,093,300
Feb 27, 2026 0 4,278,400
Feb 20, 2026 0 4,774,100
Feb 13, 2026 0 4,650,800
Feb 6, 2026 0 5,067,800
Company Profile
Kidswell Bio Corporation is a drug discovery venture originating from Hokkaido University. The company focuses on biopharmaceuticals, biosimilars, antibody drugs, and pediatric medicines.
Sector
Pharmaceuticals
Kidswell Bio Corporation, a drug discovery venture born out of Hokkaido University, initially operated in three business areas: biopharmaceuticals, biosimilars, and cell therapy (regenerative medicine). However, to maximize corporate value and achieve rapid stock price recovery and growth, the company has shifted its strategy to concentrate management resources on the biosimilar business, which provides a stable revenue base, and the cell therapy business, which serves as a growth foundation. In the biosimilar business, the company has been involved in the development of four products, establishing a stable revenue base through sales of launched products. In the cell therapy business, Kidswell Bio is advancing the development of regenerative medicine products utilizing stem cells from deciduous tooth dental pulp (SHED). The company is responsible for manufacturing process development and active pharmaceutical ingredient supply in the biosimilar business, and covers from basic research to manufacturing in the cell therapy business. Both business segments emphasize partnerships with pharmaceutical companies, and the company is actively working to expand its operations.